L. Banerjee

Recent Developments in the Management of T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma

A. Fielding, D. Marks, L. Banerjee, 2012, Current Hematologic Malignancy Reports.

Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.

C. Billottet, B. Vanhaesebroeck, A. Khwaja, 2009, Cancer research.

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

C Shepherd, L Banerjee, C W Cheung, 2012, Leukemia.

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

J. Burke, J. Briones, P. Abrisqueta, 2021, The Lancet. Haematology.

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

A. López-Guillermo, E. González-Barca, P. Abrisqueta, 2021 .

Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.

C. Billottet, B. Vanhaesebroeck, A. Khwaja, 2009, Cancer research.